What Is Finegoldia Magna? Causes, Symptoms & Treatment

Finegoldia magna is a Gram-positive, oxygen-intolerant bacterium that normally lives harmlessly on human skin and mucosal surfaces but can turn into an opportunistic pathogen when it reaches deeper tissues or encounters a weakened immune system. It was formerly classified as Peptostreptococcus magnus until it was reclassified in 1999, and the older name still appears in some medical literature, which can cause confusion. Despite its status as a quiet member of the skin microbiome, F. magna has been linked to infections ranging from chronic wound complications and joint implant failures to life-threatening endocarditis on prosthetic heart valves.

Where Finegoldia Magna Normally Lives

F. magna is an obligate anaerobe, meaning it thrives only in environments with little or no oxygen. On a healthy person, it colonizes the skin surface, the gastrointestinal tract, and the genitourinary tract.¹ It is part of the normal human microbiota and, under ordinary circumstances, causes no trouble. Many people carry it without ever knowing. The bacterium’s preference for low-oxygen niches explains why it tends to cause problems in deep wounds, around implanted devices, and in tissues where blood supply is compromised, since these are all settings where oxygen levels drop enough for the organism to flourish.

How a Harmless Skin Bacterium Becomes Dangerous

The shift from commensal to pathogen involves several tools that F. magna uses to establish itself in tissue and evade the immune system. Researchers have identified a handful of key virulence factors that help explain why this otherwise unassuming microbe can cause serious infections.

One important weapon is Protein L, a surface protein that binds to human antibodies. Protein L has multiple antibody-binding domains, which allow the bacterium to coat itself in the host’s own immune molecules and effectively camouflage its surface.² Beyond camouflage, Protein L triggers strong inflammatory responses. In laboratory studies, it caused immune cells called neutrophils to release a cascade of inflammatory signaling molecules, and in animal models it provoked significant lung inflammation through a pathway that depended on alveolar macrophages rather than on the antibody binding itself.³ So Protein L pulls double duty: it helps the bacterium hide and, paradoxically, it also ramps up harmful inflammation in surrounding tissues.

Another virulence factor is SufA, an enzyme that breaks down human fibrinogen, the protein your body uses to form blood clots. By degrading fibrinogen, SufA prevents the formation of fibrin networks, which your body would otherwise use to wall off the infection site.⁴ SufA also chews up histones, antimicrobial proteins that the immune system deploys against invading bacteria.⁵ A third virulence protein called FAF (F. magna adhesion factor) helps the bacterium stick to skin cells and penetrate the skin barrier.⁶ Together, FAF, Protein L, and SufA also trigger neutrophils to release inflammatory cytokines, further fueling tissue damage.⁷

Types of Infections Caused by Finegoldia Magna

F. magna does not cause a single signature disease. Instead, it shows up across a surprisingly wide range of clinical settings. What these infections have in common is that they tend to involve sites with low oxygen, foreign material, or compromised tissue.

Skin, Soft Tissue, and Chronic Wounds

Skin and soft-tissue infections are probably the most common clinical context for F. magna. It is regularly found in chronic wound cultures, particularly in diabetic foot ulcers. A review of anaerobes in diabetic foot infections noted that the growing understanding of anaerobic species like F. magna, their virulence factors, and their role in wound progression supports combining surgical debridement with antibiotic therapy that covers anaerobes in moderate-to-severe cases.⁸ Chronic wounds are rarely infected by a single species. F. magna often participates in polymicrobial communities alongside common wound pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis.⁹ These mixed communities form biofilms that are notoriously hard to treat, and the interactions among species can either accelerate or worsen the wound-healing process.¹⁰

Beyond chronic wounds, case reports describe F. magna causing large spontaneous subcutaneous abscesses and even necrotizing soft tissue infections in people with weakened immune defenses.¹¹ A recent case report also documented F. magna as the culprit behind a breast abscess in a non-lactating adolescent, successfully treated with a combination of catheter-based drainage and targeted antibiotic irrigation.¹²

Orthopedic Implant Infections

F. magna can colonize prosthetic joints and other orthopedic hardware. A study of nine patients with F. magna joint implant infections found that although the bacterium was generally susceptible to antibiotics, surgical treatment combined with long-term antibiotic therapy was typically necessary to clear the infection.¹³ The reason antibiotics alone often fall short ties back to biofilm. Once F. magna forms a biofilm on an implant surface, the bacterial community becomes physically shielded from both antibiotics and immune cells, making infection chronic and difficult to eradicate without removing or replacing the device.¹⁴

Prosthetic Valve Endocarditis

Perhaps the most dangerous infection F. magna can cause is endocarditis, particularly on prosthetic heart valves. This is rare but serious. A review of published cases found that F. magna endocarditis typically develops within about 60 days after valve replacement surgery, with prosthetic valves involved in roughly 85% of reported cases. The mortality rate in these cases was around 28%.¹⁵ A separate analysis placed the mortality for confirmed F. magna endocarditis at 25%, with both fatal cases in the literature occurring despite both surgical and antibiotic treatment.¹⁶ What makes these cases especially tricky is that standard blood cultures frequently come back negative; in most reported F. magna endocarditis cases, the definitive diagnosis was only made by culturing tissue obtained during surgery.¹⁶

Who Is Most at Risk

Because F. magna is an opportunist, the people most vulnerable to infection are those whose natural defenses are already compromised. Diabetes stands out as the single most prominent risk factor. In a review of skin and soft-tissue infections caused by F. magna, diabetes was present in the majority of patients: eight out of thirteen cases in one analysis.¹⁷ The connection makes biological sense: diabetes impairs blood flow and immune function in the skin, creating low-oxygen environments where anaerobes like F. magna can gain a foothold.

Other high-risk groups include people with prosthetic heart valves or orthopedic implants (as discussed above), people on immunosuppressive medications, and anyone with chronic wounds that stay open for extended periods. A case of necrotizing soft tissue infection on the chest wall was reported in an immunocompromised patient, highlighting that severe immune suppression can enable F. magna, even alongside other rare organisms, to cause life-threatening tissue destruction.¹¹ For healthy individuals without implants, chronic wounds, or immune problems, F. magna infection is quite uncommon.

Why Finegoldia Magna Is Easy to Miss in the Lab

Diagnosing an F. magna infection can be genuinely difficult. As an obligate anaerobe, it will not grow on standard aerobic culture plates. If a lab does not specifically set up anaerobic cultures and give them enough time to grow, F. magna will simply be absent from the results. This is a real problem in clinical settings where anaerobic cultures are not always ordered or where they are discarded too early.

Even when anaerobic cultures are performed, the bacterium can be slow-growing and tricky to identify by traditional methods. Modern identification relies heavily on MALDI-TOF mass spectrometry, a technology that identifies bacteria by their protein fingerprint. In one case report, MALDI-TOF identified F. magna from a breast cyst with 99.9% confidence after the colony was picked from an anaerobic blood agar plate.¹⁸ In endocarditis cases, where standard blood cultures often fail to detect it, tissue cultures from surgical specimens and molecular techniques like 16S ribosomal RNA gene sequencing have been used to confirm the diagnosis.¹⁹

The diagnostic challenge matters because delayed identification means delayed targeted treatment. If F. magna is not identified, clinicians may use antibiotics that fail to cover it, allowing the infection to become entrenched.

Antibiotic Treatment

The good news is that F. magna generally remains susceptible to several commonly used antibiotics. A study of F. magna strains from prosthetic joint infections found that all tested strains were susceptible to benzylpenicillin, amoxicillin-clavulanic acid, and metronidazole, while about 75% were susceptible to clindamycin. The study’s authors recommended benzylpenicillin, amoxicillin-clavulanic acid, or metronidazole as first-line treatment options for F. magna infections without waiting for individual susceptibility testing.²⁰

That said, clindamycin resistance is a real concern. A separate analysis of 42 F. magna isolates found marked resistance to clindamycin in about 9.5% of strains, while only about 2.4% showed resistance to penicillin.²¹ Clindamycin is frequently prescribed empirically for suspected anaerobic infections, which means that in a minority of F. magna cases, the go-to empiric choice could fail. This is one reason researchers emphasize that susceptibility testing, though not always performed for anaerobes in routine practice, becomes particularly important when F. magna is identified.

When Surgery Is Part of the Answer

For many F. magna infections, antibiotics alone are not enough. The bacterium’s ability to form biofilms on foreign materials like orthopedic hardware and prosthetic heart valves means the infection can persist even under antibiotic pressure. In orthopedic implant infections, surgical intervention to remove or exchange the infected device, combined with extended courses of antibiotics, is often the standard approach.¹³

In soft-tissue infections, surgical debridement to physically remove infected and dead tissue plays a critical role, especially in diabetic foot ulcers and abscesses. For chronic or deep-seated infections, some creative approaches have been reported. In the breast abscess case in an adolescent, surgeons used ultrasound-guided cavity debridement followed by placement of a catheter for continuous irrigation with metronidazole directly into the abscess cavity. The approach cleared the infection without recurrence and preserved tissue cosmesis.¹² For prosthetic valve endocarditis, reoperation to replace the infected valve is frequently necessary, though outcomes remain guarded given the high mortality rate described earlier.

The Biofilm Problem

Biofilm formation deserves its own discussion because it is central to why F. magna infections are so stubborn. A biofilm is a community of bacteria embedded in a self-produced matrix of sugars and proteins that clings to a surface. Once established, a biofilm physically blocks antibiotics from penetrating to the bacteria inside and shields the colony from immune cells. F. magna forms biofilms not only on implanted devices but also in chronic wounds, and it appears that different nutrients available at the infection site influence whether the bacterium attaches to a surface or forms floating clumps called aggregates.²² Recent genetic research has identified a specific adhesin protein that F. magna uses to form stress-tolerant aggregates, which may help the organism survive antimicrobial treatment.²³

This ability to form persistent biofilms in part explains why F. magna infections often need surgical source control rather than antibiotics alone. It also explains why infections can recur if a contaminated device is not fully removed. For chronic wounds, the polymicrobial biofilm adds another layer of complexity. F. magna does not just coexist with other wound bacteria; the species in a mixed biofilm interact in ways that can amplify resistance and impair healing.

Finegoldia Magna in Dogs and Cats

F. magna is not exclusively a human pathogen. It has been found in the normal flora of both dogs and cats.¹ In dogs, next-generation sequencing studies have identified F. magna as one of the anaerobic bacteria enriched in clinically affected ears, a finding that was somewhat surprising because anaerobic bacteria were not previously recognized as common culprits in canine ear infections.²⁴ Veterinary reviews have since listed F. magna among the organisms frequently isolated from canine otitis externa.²⁵

The clinical significance of F. magna in veterinary medicine is still being worked out. Conventional culture-based diagnostics often miss anaerobes in animal samples for the same reasons they miss them in human labs: without dedicated anaerobic culture conditions, the organism simply does not grow. As molecular diagnostic tools become more common in veterinary practice, it is likely that F. magna will be recognized more frequently as a contributor to chronic or treatment-resistant ear and skin infections in companion animals.

The Taxonomy Confusion

If you dig into the medical literature, you will encounter F. magna under its old name, Peptostreptococcus magnus, especially in papers published before about 2000. The reclassification happened in 1999, when researchers determined that the organism was distinct enough from other Peptostreptococcus species to warrant its own genus.²⁶ The new genus was named Finegoldia after the American microbiologist Sydney Finegold, who spent decades studying anaerobic bacteria. For clinicians and patients, the practical consequence is that older case reports about Peptostreptococcus magnus endocarditis or wound infections are describing the same organism. If a lab report comes back with either name, the treatment considerations are the same.